What is SubjectWell?
SubjectWell operates as a specialized marketplace for clinical trial patient recruitment, effectively bridging the gap between pharmaceutical research sponsors and the general population. By prioritizing a risk-free model, the company addresses one of the most significant bottlenecks in drug development: the timely and efficient enrollment of diverse patient cohorts. Its platform provides patients with increased transparency and choice, while simultaneously offering research sites a streamlined pathway to identify qualified candidates for innovative treatment options. As a key player in the health tech ecosystem, SubjectWell is redefining how clinical research awareness is cultivated and how patient-centric recruitment is executed at scale.
How much funding has SubjectWell raised?
SubjectWell has raised a total of $45.9M across 4 funding rounds:
Series A
$10M
Debt
$350K
Debt
$542K
Series B
$35M
Series A (2019): $10M with participation from Geekdom Fund, Windham Venture Partners, and Healthy Ventures
Debt (2020): $350K led by PPP
Debt (2021): $542K supported by PPP
Series B (2022): $35M featuring Healthy Ventures, Venture Asset Management, Geekdom Fund, Windham Venture Partners, and Bertelsmann SE
Key Investors in SubjectWell
Geekdom Fund
Geekdom Fund is a venture capital firm dedicated to connecting entrepreneurs with investors, providing significant support and resources to portfolio companies with a focus on high-growth potential startups.
Windham Venture Partners
Windham Venture Partners is a New York City based venture capital firm focused on healthcare, with particular emphasis on medical technology and digital health innovation.
Healthy Ventures
Healthy Ventures is a purpose-built, early-stage venture investor focused on health tech, aiming to support the scaling and diversification of healthcare technologies through robust market adoption strategies.
What's next for SubjectWell?
With this major strategic investment, SubjectWell is poised to deepen its market penetration and enhance its technological infrastructure. The company's focus will likely shift toward scaling its digital recruitment capabilities and expanding its network of research sites to meet the growing demand for decentralized clinical trials. By utilizing this capital to refine its go-to-market strategy, SubjectWell aims to solidify its position as an essential utility in the global healthcare infrastructure. Future growth will likely be driven by increased adoption of its patient-matching algorithms and strategic partnerships with major pharmaceutical entities, ensuring that the company remains at the forefront of clinical research innovation.
See full SubjectWell company page
